Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9BYE2
UPID:
TMPSD_HUMAN
Alternative names:
Membrane-type mosaic serine protease
Alternative UPACC:
Q9BYE2; B4DTM9; E9PIJ5; E9PRA0; F8WAJ3; J3KQC6; Q1RMF8; Q86YM4; Q96JY8; Q9BYE1
Background:
Transmembrane protease serine 13, also known as a membrane-type mosaic serine protease, plays a pivotal role in various biological processes. It is a serine protease that cleaves the proforms of PRSS8/prostasin and HGF, leading to the activation of these proteins. This activation promotes MAPK signaling and is crucial for the formation of the stratum corneum and the epidermal barrier in embryos, highlighting its significance in developmental biology.
Therapeutic significance:
Understanding the role of Transmembrane protease serine 13 could open doors to potential therapeutic strategies. Its involvement in the activation of key proteins and signaling pathways underscores its potential as a target in drug discovery efforts aimed at treating developmental disorders and diseases related to epidermal barrier dysfunction.